Even before postmenopausal osteoporosis was described, in the 1930s, the young intact rat was the model used to first show anabolic (bone-building) properties of parathyroid hormone (PTH) (15), forming the basis of teriparatide therapy (16). Here, PTH is linked to postmenopausal osteoporosis.